Development and multinational validation of a multiple myeloma-specific comorbidity index using real-world cohorts: CAREMM-2108.
A new tool predicts survival outcomes more accurately in myeloma patients, potentially improving how doctors match treatments to individual needs.
A new myeloma-specific comorbidity index (MM-CI) was developed from 17,273 patients and validated across multinational cohorts. It outperforms existing tools for predicting survival and may support real-world treatment decisions.
What the study was
- Study design
- Retrospective cohort with external validation
- Population
- Multiple myeloma patients (Korean and Japanese cohorts)
- Sample size
- 19060
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Blood Cancer Journal
Why it surfaced
Large multinational validation study with clear clinical applicability. Strong design quality for a retrospective study.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.